Claims

[Claim 1]

The use of:

hyaluronic acid; and

mesenchymal stem cells,

in the manufacture of a medicament for the treatment of a cartilage damage-associated disease wherein the mesenchymal stem cells are to be administered subsequent to the hyaluronic acid.

[Claim 2]

The use of mesenchymal stem cells in the manufacture of a medicament for the treatment of a cartilage damage-associated disease, wherein the mesenchymal stem cells are to be administered subsequent to hyaluronic acid.

[Claim 3]

The use of hyaluronic acid in the manufacture of a medicament for the treatment of a cartilage damage-associated disease, wherein mesenchymal stem cells are to be administered subsequent to the hyaluronic acid.

[Claim 4]

The use of claim 1, 2 or 3, wherein the hyaluronic acid is in a solution that has a concentration of 0.5% (w/v) to 2.0% (w/v) of hyaluronic acid.

[Claim 5]

The use as claimed in claim 1, 2 or 3, wherein the mesenchymal stem cells are contained in a solution in an amount of 1.0×10^5 cells/ml to 1.0×10^8 cells/ml.

[Claim 6]

The use as claimed in claim 1, 2 or 3, wherein the hyaluronic acid is in a solution that has a concentration of 0.5% (w/v) to 2.0% (w/v) of hyaluronic acid, and the mesenchymal stem cells are contained in an amount of 1.0×10^5 cells/ml to 1.0×10^8 cells/ml.

[Claim 7]

The use as claimed in claim 1, 2 or 3, wherein the mesenchymal stem cells are derived from umbilical cord blood.

[Claim 8]

The use as claimed in claim 1, 2 or 3, wherein the cartilage damage-associated disease is osteoarthritis, meniscus tear, arthrosis deformans, or chondromalacia.

[Claim 9]

The use as claimed in claim 8, wherein a site where the osteoarthritis occurs is jaw joint, shoulder joint, elbow joint, wrist joint, finger joint, spine joint, hip joint, knee joint, ankle joint, or toe joint.

[Claim 10]

The use as claimed in claim 1, 2 or 3, wherein the hyaluronic acid and the mesenchymal stem cells are to be administered intraarticularly.